In the study, we investigate the role of FOXM1 in the resistance of lung adenocarcinoma cells to gefitinib, and define a novel regulatory pathway directly linking the MET/AKT signaling axis to FOXM1. Here, AKT1 is linked to lung adenocarcinoma.